STOCKHOLM, April 5,
2022 /PRNewswire/ -- Medivir AB (Nasdaq
Stockholm: MVIR) today announces that the Annual Report for
2021 now is available at the company's
website: www.medivir.com. 2021 started off with the
licensing of birinapant to IGM Biosciences, which in November
initiated a clinical study in solid tumors with its own DR5 agonist
antibody and birinapant. A successful financing that included
participation from specialist investors was also carried out at the
beginning of the year. Medivir's cutting-edge project
fostroxacitabine bralpamide showed positive study results and
entered a new clinical phase in December when the treatment of the
first patient with HCC in the phase 1b/2a combination study began. Medivir
furthermore strengthened the business development opportunities for
remetinostat and several positive results from
investigator-initiated studies with remetinostat were presented
during the year.
This and much more can be found in Medivir's Annual Report 2021,
published today at the website;
https://www.medivir.com/investors/reports#FinancialReports2021
For additional information, please
contact
Magnus Christensen,
CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
fostroxacitabine bralpamide (MIV-818), a pro-drug designed to
selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-2021-annual-report-published,c3540203
The following files are available for download:
|
https://mb.cision.com/Main/652/3540203/1559825.pdf
|
Annual Report 2021
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/medivir-2021-annual-report-published-301517758.html
SOURCE Medivir
